SMARCA4 and cancer: We treated two BRG1-deficient cancer cell lines that harbored either scrambled or anti-BRG1 shRNA with either Sorafenib or PPP for 96 hours and measured the expression of BRG1 and the number of cells over time to determine the growth rate.